Ignite Creation Date:
2025-12-25 @ 4:18 AM
Ignite Modification Date:
2026-03-06 @ 6:14 PM
Study NCT ID:
NCT03518320
Status:
TERMINATED
Last Update Posted:
2024-08-27
First Post:
2018-04-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
Sponsor:
Taris Biomedical LLC
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Bladder Cancer TNM Staging Primary Tumor (T) T2 | View |
| None | Bladder Cancer TNM Staging Primary Tumor (T) T2A | View |
| None | Bladder Cancer TNM Staging Primary Tumor (T) T2B | View |
| None | Bladder Cancer TNM Staging Primary Tumor (T) T3 | View |
| None | Bladder Cancer TNM Staging Primary Tumor (T) T3A | View |
| None | Bladder Cancer TNM Staging Primary Tumor (T) T3B | View |
| None | Bladder Cancer TNM Staging Regional Lymph Node (N) N0 | View |
| None | Bladder Cancer TNM Staging Regional Lymph Node (N) N1 | View |
| None | Bladder Cancer TNM Staging Distant Metastasis (M) M0 | View |